Info

Infinity Pharmaceuticals, Inc. (IPI) has developed a pipeline of product candidates for multiple cancer indications. The Company’s lead product candidate, retaspimycin hydrochloride for injection (formerly known as IPI-504), or retaspimycin, is an intravenously administered small molecule inhibitor of heat shock protein 90 (Hsp90). As of February 29, 2008, retaspimycin was being evaluated as a single agent in three disease-focused clinical trials, including a Phase I trial in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas (STS), the Phase II portion of a Phase I/II trial in patients with advanced non-small cell lung cancer (NSCLC), and a Phase II trial in patients with hormone-resistant prostate cancer (HRPC).